MedPacto to Expand Global Partnerships at BIO USA

MedPacto, an innovative new drug development company, announced on June 10 that it will participate in the 'BIO International Convention (BIO USA) 2025' to be held in Boston, USA from June 16 to 19, aiming to expand global partnerships and seek technology transfer opportunities.

MedPacto will be represented by President Woo Jeongwon and other executives and staff at BIO USA. The company plans to pursue strategic collaborations with global pharmaceutical companies and research institutions, focusing on its next-generation immuno-oncology candidate 'MP010'.

'MP010' is a new anti-cancer pipeline from MedPacto. It is an innovative anti-cancer drug candidate that destroys and modifies the extracellular matrix (ECM), a component of the tumor microenvironment (TME), thereby promoting the infiltration and activation of tumor-attacking immune cells that were previously strongly suppressed.

In particular, 'MP010' demonstrated a high complete response rate as a monotherapy in preclinical studies for malignant pancreatic cancer and triple-negative breast cancer, proving its potential as a global new drug.

Additionally, MedPacto will share its rare cancer treatment strategies, including the use of 'Vactosertib', a TGF-beta inhibitor, for osteosarcoma and other rare cancers with global pharmaceutical companies and research institutions, and will also explore joint development opportunities.

Woo Jeongwon, President of MedPacto, stated, "Actively pursuing partnerships for 'MP010' through participation in several recent overseas events is an important step for preparing clinical trials and simultaneously entering the global market. We will strive to introduce our outstanding pipelines to the global market and establish substantial cooperative relationships."

Prior to this, MedPacto also participated in the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA from May 30 to June 3, where the company consulted with numerous corporate representatives, professors, and researchers to review its development strategies.

BIO USA, organized annually by the Biotechnology Innovation Organization (BIO), is the world's largest bio-business event. This year, approximately 20,000 participants from about 80 countries around the world are expected to attend.